NCT02414685View on ClinicalTrials.gov

First Line TIP in Poor Prognosis TGCTs.

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Germ Cell Tumor
Interventions
DRUG

Paclitaxel

paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements

DRUG

Ifosfamide

paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements

DRUG

Cisplatin

paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements

Trial Locations (1)

83310

National Cancer Institute, Bratislava

All Listed Sponsors
lead

National Cancer Institute, Slovakia

OTHER_GOV

NCT02414685 - First Line TIP in Poor Prognosis TGCTs. | Biotech Hunter | Biotech Hunter